A new gadolinium-based contrast agent for magnetic resonance imaging of brain tumors: Kinetic study on a C6 rat glioma model
✍ Scribed by Emmanuel Fonchy; Hana Lahrech; Anne François-Joubert; Roger Dupeyre; Soraya Benderbous; Claire Corot; Régine Farion; Christophe Rubin; Michel Décorps; Chantal Rémy
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 275 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
T~1~‐weighted magnetic resonance imaging (MRI) was used to evaluate the potential interest of a new Gd‐based contrast agent, termed P760, to characterize brain tumor heterogeneity and vascularization and to delineate regions containing permeable vessels. The C6 rat glioma model was used as a model of high‐grade glioblastoma. The signal enhancement was measured as a function of time in the vascular compartment and in different regions of interest (ROIs) within the tumor after the injection of 0.02 mmol kg^−1^ of P760. The results were compared to those obtained after the injection of 0.1 mmol kg^−1^ of Gd‐DOTA. We showed that P760, in spite of a Gd concentration five times smaller, produces an enhancement in the blood pool similar to that produced by Gd‐DOTA. It was shown that P760 makes possible an excellent delineation of regions containing vessels with a damaged blood‐brain barrier (BBB). Images acquired 5–10 minutes after P760 injection showed the location of permeable vessels more accurately than Gd‐DOTA‐enhanced images. The enhancement produced in the tumor by P760 was, however, less than that produced by Gd‐DOTA. The extravasation and/or diffusion rate of P760 in the interstitial medium were found to be strongly reduced, compared to those found with Gd‐DOTA. This study suggests that the new contrast agent has promising capabilities in clinical imaging of brain tumors. J. Magn. Reson. Imaging 2001;14:97–105. © 2001 Wiley‐Liss, Inc.